Tempus and the Parker Institute for Cancer Immunotherapy Work Together to Analyze Data to Help Inform Immunotherapy Treatments

Tempus and the Parker Institute for Cancer Immunotherapy Work Together to Analyze Data to Help Inform Immunotherapy Treatments

NEWS

Tempus, a technology company focused on helping doctors personalize cancer care by collecting and analyzing large volumes of molecular and clinical data, and the Parker Institute for Cancer Immunotherapy will work together to analyze clinical and molecular data to better determine which patients will have a positive response to immunotherapy treatment.

Utilizing next-generation sequencing, machine learning and bioinformatics, Tempus will analyze select Parker Institute data sets for relevant patterns that can help inform which immunotherapies are most likely to be effective in a given cohort of patients.

“In oncology, and across healthcare more broadly, datasets are small and disorganized, which means that for treatments such as immunotherapy, there is often too little data to discern larger patterns of response, including adverse events,” said Eric Lefkofsky, founder and CEO at Tempus. “We look forward to furthering our work with the Parker Institute as we work to collect and utilize data at scale, in an effort to usher in the age of precision medicine.”